| Literature DB >> 35310343 |
Tongxia Jin1,2, Di Cheng1, Guanyu Jiang3, Wenqian Xing1,2, Peiwen Liu1,2, Bin Wang1, Weiping Zhu1,2, Haitao Sun3, Zhenrong Sun3, Yufang Xu1, Xuhong Qian1,2.
Abstract
Photodynamic (PDT) and photothermal therapies (PTT) are emerging treatments for tumour ablation. Organic dyes such as porphyrin, chlorin, phthalocyanine, boron-dipyrromethene and cyanine are the clinically or preclinically used photosensitizer or photothermal agents. Development of structurally diverse near-infrared dyes with long absorption wavelength is of great significance for PDT and PTT. Herein, we report a novel near-infrared dye ML880 with naphthalimide modified cyanine skeleton. The introduction of naphthalimide moiety results in stronger electron delocalization and larger redshift in emission compared with IR820. Furthermore, ML880 is co-loaded with chemotherapeutic drug into ROS-responsive mesoporous organosilica (RMON) to construct nanomedicine NBD&ML@RMON, which exhibits remarkable tumor inhibition effects through PDT/PTT/chemotherapy in vivo.Entities:
Keywords: Combination therapy; Drug delivery system; Integration strategy; Near-infrared dye; Phototherapy
Year: 2021 PMID: 35310343 PMCID: PMC8892148 DOI: 10.1016/j.bioactmat.2021.12.009
Source DB: PubMed Journal: Bioact Mater ISSN: 2452-199X
Scheme 1(A) The synthesis route of NIR fluorophore ML880; (B) The schematic illustration of the preparation and function of nanohybrids.
Photophysical characterization of ML880 in different solvents.
| ML880 | ΦF (%) | |||
|---|---|---|---|---|
| PBS | 936 | 58000 | ||
| DMSO | 880 | 912 | 88390 | 11.1 |
| MeCN | 862 | 886 | 36350 | 13.8 |
| DMF | 868 | 901 | 18600 | 13.1 |
| MeOH | 856 | 884 | 45890 | 8.2 |
| EtOH | 862 | 892 | 41720 | 10.1 |
Fig. 1The structure and normalized absorbance and emission spectrum of IR820 (A, B) and ML880 (D,E) in DMSO. The HOMO and LUMO distributions (isovalue = 0.01 a.u.) of IR820 (C) and ML880 (F) based on the optimized S1 geometries.
Fig. 2PTT and PDT effects of small molecular dye ML880. Temperature curves of ML880 in PBS solutions at different concentrations (A) and different laser power densities (B). (C) Fluorescence images and (D) ROS levels of DCFH-DA stained HepG2 cells with different treatments. Scale bar: 25 μm ***P < 0.001.
Fig. 3Property assessment of nanohybrid NBD&ML@RMON. (A) DLS of RMON and RMON co-incubated with H2O2 (100 μM) for 48 h. (B) TEM and (C) SEM image of NBD&ML@RMON. (D) Photothermal images of NBD&ML@RMON (1 mg/mL) under 880 nm laser irradiation (1 W cm−2). (E) Temperatures of the solutions of NBD&ML@RMON upon irradiating with an 880 nm laser (1 W cm−2) for 500 s and then stopping the irradiation. (F) Graph of the cooling period of the time versus the negative natural logarithm of the temperature.
Fig. 4Cell viability of HepG2 cells incubated with NBD@RMON, ML@RMON and NBD&ML@RMON at various concentrations (A) after NIR light irradiation (880 nm, 1 W cm−2, 5 min) and (B) in the dark. (C) Dark cytotoxicity of L929 cells incubated with NPs. (D) CLSM images of HepG2 cells subjected to different treatments according to the live and dead cell assays (green fluorescence, calcein AM staining living cells; and red fluorescence, PI staining dead cells; scale bar = 100 μm).
Fig. 5(A) Photothermal imaging of the tumor region under 880 nm laser irradiation (1 W cm−2, 5 min). (B) In vivo drug distribution in mice after 24h with free NBDHEX and NBD&ML@RMON.
Fig. 6In vivo assessment of NBD&ML@RMON. (A) Scheme of the timeline of experimental design. (B) Tumor volume growth curves of HepG2 tumor-bearing mice treated with various NPs. (C) Body weight changes of mice during different treatments. (D) Photos and (E) tumor weight of the dissected tumors obtained after 15-day therapy. (F) Tumor growth inhibition ratio after various treatments. (G) H&E staining and (H) CLSM images of TUNEL assay of the dissected tumor after 15-day therapy. Scale bar: 100 μm ***P < 0.001.
Fig. 7Western blotting analysis of mitochondrial apoptotic pathway associated proteins in tumor tissues after therapy.